Outlook Therapeutics, Inc. (OTLK) financial statements (2022 and earlier)

Company profile

Business Address 485 ROUTE 1 SOUTH
ISELIN, NJ 08830
State of Incorp. DE
Fiscal Year End September 30
SIC 2836 - Biological Products, Except Diagnostic Substances (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in thousands)

12/31/2021
TTM
9/30/2021
9/30/2020
9/30/2019
9/30/2018
9/30/2017
9/30/2016
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments70,15114,47712,5368,0161,7173,1862,352
Cash and cash equivalents70,15114,47712,5368,0161,7173,1862,352
Prepaid expense     2001,980
Assets held-for-sale, not part of disposal group   500   
Other undisclosed current assets7,3167,0315,4084,9861,5855191,347
Total current assets:77,46721,50817,94413,5023,3023,9055,678
Noncurrent Assets
Operating lease, right-of-use asset101111167 
Property, plant and equipment1231643273,17618,49016,08916,959
Long-term investments and receivables830854     
Long-term investments830854     
Restricted cash and investments      216
Other noncurrent assets1571751,294457491740853
Total noncurrent assets:1,2111,3031,7893,63318,98116,82918,027
TOTAL ASSETS:78,67822,81119,73317,13522,28320,73423,706
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities7,1665,77912,0098,76011,92420,64413,048
Accounts payable2,5462,1962,3952,2783,61010,9545,072
Accrued liabilities2,7641,7267,7574,6236,4587,3376,122
Taxes payable1,8571,8571,8571,8591,8562,3521,855
Debt12,739931801,026587394586
Due to related parties  3,613    
Deferred revenue and credits3,0881,213
Other undisclosed current liabilities444318710,50419,5314,6135,590
Total current liabilities:19,9496,75215,88920,29032,04228,73820,437
Noncurrent Liabilities
Long-term debt and lease obligation9,63310,929947503,5521792,555
Long-term debt, excluding current maturities9,60410,88690450981512,234
Finance lease, liability131642 
Capital lease obligations3,45328321
Operating lease, liability1627  
Liabilities, other than long-term debt   3,9433,5157,0375,915
Deferred revenue and credits4,4675,153
Other liabilities   3,9433,5152,570761
Other undisclosed noncurrent liabilities257496713,6223,98515,507 
Total noncurrent liabilities:9,90611,4521,0177,61511,05222,7238,469
Total liabilities:29,85518,20416,90627,90543,09451,46028,906
Temporary equity, carrying amount   5,3594,7342,924 
Stockholders' equity
Stockholders' equity attributable to parent48,8234,6072,826(16,129)(25,545)(33,651)(5,200)
Common stock2,2431,7651,272286722249228
Additional paid in capital403,927345,726291,274238,065190,040152,315141,965
Accumulated deficit(357,346)(342,883)(289,720)(254,480)(216,307)(186,215)(147,394)
Total stockholders' equity:48,8234,6072,826(16,129)(25,545)(33,651)(5,200)
TOTAL LIABILITIES AND EQUITY:78,67822,81119,73317,13522,28320,73423,706

Income statement (P&L) ($ in thousands)

12/31/2021
TTM
9/30/2021
9/30/2020
9/30/2019
9/30/2018
9/30/2017
9/30/2016
Revenues   8,1463,0883,8122,980
Gross profit:   8,1463,0883,8122,980
Operating expenses(50,685)(51,727)(36,841)(44,445)(32,732)(39,692)(54,738)
Operating loss:(50,685)(51,727)(36,841)(36,299)(29,644)(35,880)(51,758)
Interest and debt expense(1,279)(5)(3,653)(4,074)(5,144)(5,626)(1,468)
Loss from continuing operations before equity method investments, income taxes:(51,965)(51,732)(40,493)(40,373)(34,788)(41,506)(53,226)
Loss from equity method investments(70)(46)     
Other undisclosed income (loss) from continuing operations before income taxes(871)(1,383)1,9822,4381,0483,158 
Loss from continuing operations before income taxes:(52,905)(53,161)(38,511)(37,935)(33,740)(38,348)(53,226)
Income tax expense (benefit)(2)(2)3,2723,4113,648(502)(103)
Net loss:(52,907)(53,163)(35,239)(34,524)(30,092)(38,849)(53,329)
Other undisclosed net loss attributable to parent(263)      
Net loss attributable to parent:(53,170)(53,163)(35,239)(34,524)(30,092)(38,849)(53,329)
Preferred stock dividends and other adjustments  (166)(625)(1,904) (2,463)
Other undisclosed net loss available to common stockholders, basic  (13,468)(891)(16,023)(1,177)(7,374)
Net loss available to common stockholders, diluted:(53,170)(53,163)(48,874)(36,040)(48,019)(40,026)(63,166)

Comprehensive Income ($ in thousands)

12/31/2021
TTM
9/30/2021
9/30/2020
9/30/2019
9/30/2018
9/30/2017
9/30/2016
Net loss:(52,907)(53,163)(35,239)(34,524)(30,092)(38,849)(53,329)
Comprehensive loss, net of tax, attributable to parent:(52,907)(53,163)(35,239)(34,524)(30,092)(38,849)(53,329)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: